Juvenescence, a life sciences company focused on increasing human longevity and treating diseases of aging, has closed $100 million in Series B funding. The investors included Grok Ventures.
Source: Press Release
Juvenescence, a life sciences company focused on increasing human longevity and treating diseases of aging, has closed $100 million in Series B funding. The investors included Grok Ventures.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.